A Phase 3 interventional study of Corever in Hypertension, sponsored by TSH Biopharm Corporation Limited. Completed at 8 sites in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by TSH Biopharm Corporation Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Hypertension with a site in Taiwan — 17 open to participants now, 20 under way, 5 of them phase 3. Hypertension · Taiwan.
Among the 116 studies in Hypertension with a site in Taiwan, this one is the 55th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2015, is one of 26 in phase 3, and was the 59th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →17 of the 116 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 18+
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 50+
Kaohsiung Armed Forces General Hospital · Sites in Taiwan
Ages 18–65
New Taipei City Medical Association · Sites in Taiwan
Medtronic Vascular · Sites in Taiwan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 27 · Phase 4 20
First in 2001; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 233 across the 90 interventional studies, 223 across the 24 observational. Of the 76 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 116 have an industry lead sponsor. The 10 most frequent:
TSH Biopharm Corporation Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
TSH Biopharm Corporation Limited has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Hypertension with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07578090Fu Jen Catholic UniversityRegional Innovation in Chronic Disease and Elderly Care | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
| NCT06819241Taichung Veterans General HospitalSelf-Management of Blood Pressure in Resistant Hypertension | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 116 studies in Hypertension with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.
The study aims to compare the effects of two doses of Corever with placebo in patients with essential hypertension. Eligible subjects who belong to one of the following subtypes are planned to be enrolled: (1) patients with essential hypertension without drug control, or (2) uncontrolled hypertension despite treatment with up to 2 antihypertensive agents. Of note, the second category will receive randomized study treatments in addition to continuing their previous medication throughout the trial. The study also wants to investigate the safety profile of Corever during treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who belong to either one of the following categories:
With essential hypertension, as measured by office BP and are not on antihypertensive treatment at screening .
With uncontrolled hypertension despite treatment with up to 2 antihypertensive agents, and the type and dose of the agents shall be maintained for at least 28 days prior to entering this trial.
Exclusion Criteria:
Patients with any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Corever
Drug: Corever
Drug: Corever
Corever
Also known as: CRTA04
Seated Office SBP reduction (SBP each visit-SBP visit 2)
To compare the change in office SBP measurements by cuff assessments after 8 weeks of treatment
Time frame: 8 weeks
Seated Office DBP reduction (DBP each visit-DBP visit 2)
1. To compare the change in office DBP measurements by cuff assessments after 8 weeks of treatment 2. To compare the percentage of subjects who achieve BP goal as measured by cuff assessments (140/90 mmHg) after 8 weeks of treatment
Time frame: 8 weeks
Safety-Adverse events
Time frame: 8 weeks
Safety-Changes in vital signs
Time frame: 8 weeks
Safety-Changes in laboratory examinations
Time frame: 8 weeks
Safety-Changes in electrocardiograms
Time frame: 8 weeks
The record gives a start of Jan 2015, a primary completion of Jun 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TSH Biopharm Corporation Limited